Steven L. Hoerter's Net Worth
$9.01 Million
Who is Steven L. Hoerter?
Steven L. Hoerter has an estimated net worth of $9.01 Million. This is based on reported shares across multiple companies, which include AGIOS PHARMACEUTICALS INC, CONSTELLATION PHARMACEUTICALS INC, Deciphera Pharmaceuticals, Inc., Clovis Oncology, Inc., Ignyta, Inc., and Oric Pharmaceuticals, Inc..
SEC CIK
Steven L. Hoerter's CIK is 0001533451
Past Insider Trading and Trends
2018 was Steven L. Hoerter's most active year for acquiring shares with 14 total transactions. Steven L. Hoerter's most active month to acquire stocks was the month of February. 2018 was Steven L. Hoerter's most active year for disposing of shares, totalling 18 transactions. Steven L. Hoerter's most active month to dispose stocks was the month of February. 2018 saw Steven L. Hoerter paying a total of $1,564,556.00 for 170,942 shares, this is the most they've acquired in one year. In 2018 Steven L. Hoerter cashed out on 114,366 shares for a total of $3,084,493.50, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
AGIOS PHARMACEUTICALS INC (AGIO) Snapshot price: $24.15
Chief Commercial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$53.39 | -$272,450.00 | 10.94K |
Mar 1 - Mar 4
| |||
Form 4
| +18.52% | 1.71K |
$58.03 | -$60,351.20 | 10.94K |
Feb 16 - Feb 19
| |||
Form 4
|
∞
| 9.23K |
$52.82 | -$304,718.58 | 9.23K |
Jan 20 - Jan 22
| |||
Form 4
|
—
|
0
|
$57.34 | -$72,078.00 |
0
|
Scheduled
|
Aug 24
| ||
Form 4
|
—
|
0
|
$62.17 | -$91,881.00 |
0
|
Scheduled
|
Jul 25
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 20
| |||
Form 4
|
—
|
0
|
$68.67 | -$118,531.00 |
0
|
Scheduled
|
Jun 22
| ||
Form 4
|
—
|
0
|
$62.76 | -$94,300.00 |
0
|
Scheduled
|
May 23
| ||
Form 4
|
—
|
0
|
$62.86 | -$94,689.50 |
0
|
Scheduled
|
Apr 23
| ||
Form 4
|
—
|
0
|
$62.21 | -$92,024.50 |
0
|
Scheduled
|
Mar 22
| ||
Form 4
|
—
|
0
|
$59.19 | -$79,683.50 |
0
|
Scheduled
|
Feb 22
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 16
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Scheduled
|
Jan 23
| ||
Form 4
|
—
|
0
|
$57.30 | -$876,750.00 |
0
|
Scheduled
|
Jan 23
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CONSTELLATION PHARMACEUTICALS INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jul 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Deciphera Pharmaceuticals, Inc. (DCPH) Snapshot price: $14.52
President and CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -72.76K |
—
|
—
|
0
|
Jun 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 15
| |||
Form 4
| +77.79% | 31.84K |
$15.37 | -$471,216.75 | 72.76K |
Dec 12 - Dec 13
| |||
Form 4
|
∞
| 40.93K |
$12.02 | -$259,255.68 | 40.93K |
Oct 28 - Oct 30
| |||
Form 4
| -100.00% | -7.50K |
$15.57 | -$116,781.75 |
0
|
Mar 21
| |||
Form 4
| -80.02% | -30.05K |
$16.00 | -$480,720.00 | 7.5K |
Scheduled
|
Feb 14 - Feb 15
| ||
Form 4
| -7.74% | -3.15K |
$9.11 | -$28,696.50 | 37.55K |
Scheduled
|
Mar 21
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 15
| |||
Form 4
| -7.18% | -3.15K |
$43.02 | -$135,499.52 | 40.7K |
Scheduled
|
Mar 18
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 16
| |||
Form 4
| +2.52% | 1.08K |
$25.40 | $27,381.20 | 43.84K |
Jan 21
| |||
Form 4
| +0.44% | 187 |
$25.40 | $4,749.80 | 42.77K |
Aug 20
| |||
Form 4
| +0.44% | 188 |
$25.40 | $4,775.20 | 42.58K |
Jul 20
| |||
Form 4
| +0.44% | 187 |
$25.40 | $4,749.80 | 42.39K |
Jun 18
| |||
Form 4
| +0.45% | 188 |
$25.40 | $4,775.20 | 42.2K |
May 28
| |||
Form 4
| +0.45% | 187 |
$25.40 | $4,749.80 | 42.02K |
Apr 21
| |||
Form 4
| -19.56% | -10.17K |
$31.45 | -$408,469.36 | 41.83K |
Scheduled
|
Mar 18 - Mar 19
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 18
| |||
Form 4
|
∞
| 52K |
—
|
—
| 52K |
Mar 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Clovis Oncology, Inc. No price found
See Remarks
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$45.51 | -$1,379,600.00 |
0
|
Scheduled
|
Mar 5
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 2
| |||
Form 4
|
—
|
0
|
$41.51 | -$609,800.00 |
0
|
Scheduled
|
Feb 17
| ||
Form 4
|
—
|
0
|
$39.01 | -$559,800.00 |
0
|
Scheduled
|
Jan 16
| ||
Form 4
|
—
|
0
|
$36.51 | -$509,800.00 |
0
|
Scheduled
|
Jan 13
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 10
| |||
Form 4
|
—
|
0
|
$42.04 | -$620,400.00 |
0
|
Jun 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Ignyta, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||